Novo Nordisk's Pipeline Paradox: Better Numbers, Bleaker Narrative
Published on 08/05/2026 at 21:40 | Redaktion boerse-global.de
The arithmetic of Novo Nordisk's current predicament is hard to reconcile. On Wednesday, the Danish drugmaker's shares climbed 2.45 percent to €39.33, a welcome bounce for investors who had just endured a seven-session slide of 12.83 percent. Yet the underlying tension remains unmistakable: the company's operating performance is improving, but the market's confidence in its growth trajectory is not following suit.
That disconnect crystallized on Tuesday when Novo Nordisk raised its full-year guidance — and still triggered a sell-off. Management now expects adjusted sales and operating profit growth of between 0 and minus 6 percent at constant exchange rates for 2026, a meaningful improvement over the previous range of minus 4 to minus 12 percent. The second quarter delivered adjusted revenue of 78.5 billion Danish kroner and operating profit of 33.4 billion kroner, the latter up 11 percent on a currency-adjusted basis.
The problem, as Mizuho Securities bluntly framed it, is that the guidance hike was "not heroic." A forecast that merely moves from "very bad" to "moderately bad" does not constitute a relief rally — particularly when the details behind the numbers tell a more troubling story.
A Pipeline Under Siege
The quarter was overshadowed by a cascade of clinical disappointments. The oral Wegovy pill generated sales of 3.22 billion kroner, narrowly missing the analyst consensus of 3.27 billion. More damaging, however, was the failure of CagriSema, the much-anticipated successor candidate, in a Phase 3 trial for Type 2 diabetes: it failed to demonstrate superior blood sugar control versus Eli Lilly's Tirzepatid in a head-to-head comparison.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Compounding the setback, the ZEUS study evaluating Ziltivekimab in patients with chronic kidney disease missed its primary endpoint of reducing cardiovascular events — despite achieving the expected inhibition of the IL-6 signaling pathway. Morningstar analyst Karen Andersen responded by removing Ziltivekimab from her revenue projections for the company entirely.
These pipeline losses carry a tangible cost. Novo Nordisk recorded a non-cash impairment charge of 6.3 billion kroner, including 4.0 billion kroner tied to the discontinuation of the investigational drug Monlunabant. Within a matter of days, two central growth hopes evaporated precisely as competitive pressure from Eli Lilly intensifies — Lilly posted second-quarter revenue of $23 billion, a 48 percent year-over-year surge that underscores the structural challenge Novo Nordisk faces in the GLP-1 market.
The Search for External Solutions
CEO Maziar Doustdar acknowledged the gravity of the situation during the earnings call, stating that the company is actively evaluating multiple "bolt-on" acquisitions to supplement its internal research pipeline. It is a candid admission that Novo Nordisk can no longer rely solely on its own laboratories to sustain its growth narrative.
The market's response has been measured skepticism rather than panic. Jefferies reaffirmed its "Hold" rating with a price target of 285 Danish kroner on Wednesday — a signal that even with the improved guidance, the investment case lacks compelling upside. The stock currently trades 28.31 percent below its 52-week high, a more meaningful barometer of investor sentiment than any single day's movement. At €38.63, the shares have shed 14.37 percent over the past seven trading days, with the technical picture showing an RSI of 34.9 — technically oversold, though that indicator carries limited fundamental weight.
Countervailing Forces
The bearish narrative, however, is not without counterpoints. Novo Nordisk continues to execute its 15 billion kroner share buyback program, purchasing approximately 1.145 million B-shares for 370.9 million kroner between July 27 and August 3. The cumulative program now stands at 12.305 million B-shares for 3.73 billion kroner — a signal that management considers the stock undervalued. Lazard Asset Management, however, reduced its position in Novo Nordisk ADRs on Sunday, a reminder that not all institutional investors share that conviction.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
There are also genuine operational bright spots. The European Commission granted approval for the Wegovy pill in July as the first oral GLP-1 treatment for weight reduction in the EU, and Italy has been confirmed as the first European launch market. Germany is expected to see the 25-mg once-daily tablet available in the third quarter of 2026. On the legal front, a Dutch court issued a preliminary injunction on Wednesday against Ceban Ziekenhuisfarmacie B.V., halting sales of a counterfeit semaglutide nasal spray for patent infringement — a victory that protects the franchise but does little to address the fundamental growth question.
What Comes Next
The near-term trajectory likely hinges on the Capital Markets Day scheduled for September 20-21, where management is expected to present long-term financial targets and its strategic response to the pipeline setbacks. The proximity to the 52-week low of €30.25 provides some cushion, and continued buybacks plus the revised guidance may help establish a floor at current levels.
But if the September presentation fails to deliver a credible plan to close the pipeline gap, the downward pressure could persist. The nine-month results due November 4 will offer the next opportunity to assess whether the operational strength of the core business can withstand the combined weight of clinical disappointments and Eli Lilly's accelerating momentum. For now, Novo Nordisk appears to be working toward a turnaround — it just hasn't yet convinced the market that it has found one.
Ad
Novo Nordisk Stock: New Analysis - 5 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
